Related Experiment Video
Updated: Mar 9, 2026

12:27
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
Published on: May 7, 2015
17.0K
Preliver transplant red cell distribution width predicts postliver transplant mortality
M Thure Caire1, Ambuj Kumar2, R Todd Stravitz3
1Hepatology and Liver Transplant, Tampa General Medical Group, Tampa, FL, USA.
Clinical Transplantation
|January 6, 2017
Summary
Red cell distribution width (RDW) can predict one-year mortality after liver transplantation. This finding offers a new tool for prognostication in liver transplant recipients.
Area of Science:
- Transplantation Medicine
- Hematology
- Clinical Prognostication
Background:
- Prognosis after liver transplantation remains challenging.
- Red cell distribution width (RDW) is linked to poor outcomes in various conditions.
- The predictive role of RDW in liver transplant recipients is not well-established.
Purpose of the Study:
- To investigate the association between pre-transplant Red cell distribution width (RDW) and one-year mortality in liver transplant recipients.
- To determine if RDW can serve as a prognostic marker for post-liver transplantation outcomes.
Main Methods:
- Retrospective cohort study of liver transplant recipients (2012-2012).
- Primary endpoint: association of RDW with one-year mortality.
- Statistical analyses included Mann-Whitney, t-tests, regression, and AUC for discrimination.
Main Results:
- RDW showed a significant positive association with one-year mortality (P<.001).
- Mean RDW was 3.9% higher in non-survivors versus survivors.
- RDW demonstrated strong predictive value (AUC=0.831), outperforming total bilirubin and INR.
Conclusions:
- This study is the first to report an association between RDW and post-liver transplantation mortality.
- Pre-transplant RDW is a valuable predictor of one-year mortality following liver transplantation.
- RDW may enhance prognostication in liver transplant candidates.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
305
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
245
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245

